Skip to content

Opening book details…

Can I read Efficacy of three BCG strains (Connaught, TICE and RIVM) with or without secondary resection (re-TUR) for intermediate/high-risk non-muscle-invasive bladder cancers: results from a retrospective single-institution cohort analysis on EtoBox?

Efficacy of three BCG strains (Connaught, TICE and RIVM) with or without secondary resection (re-TUR) for intermediate/high-risk non-muscle-invasive bladder cancers: results from a retrospective single-institution cohort analysis by Francesco Del Giudice; Gian Maria Busetto; Martin S. Gross; Martina Maggi; Alessandro Sciarra; Stefano Salciccia; Matteo Ferro; Isabella Sperduti; Simone Flammia; Vittorio Canale; Benjamin I. Chung; Simon L. Conti; Michael L. Eisenberg; Eila C. Skinner; Ettore De Berardinis is a Medicine article available to read on EtoBox.

What is Efficacy of three BCG strains (Connaught, TICE and RIVM) with or without secondary resection (re-TUR) for intermediate/high-risk non-muscle-invasive bladder cancers: results from a retrospective single-institution cohort analysis about?

## Abstract ## Purpose (I) To evaluate the clinical efficacy of three different BCG strains in patients with intermediate-/high-risk non-muscle-invasive bladder cancer (NMIBC). (II) To determine the importance of performing routine secondary resection (re-TUR) in the setting of BCG maintenance protocol for the three strains. ## Methods NMIBCs who received an adjuvant induction followed by a maintenance schedule of intravesical immunotherapy with BCG Connaught, TICE and RIVM. Only BCG-naïve and those treated with the same strain over the course of follow-up were included. Cox proportional hazards model was developed according to prognostic factors by the Spanish Urological Oncology Group (CUETO) as well as by adjusting for the implementation of re-TUR. ## Results n = 422 Ta-T1 patients (Connaught, n = 146; TICE, n = 112 and RIVM, n = 164) with a median (IQR) follow-up of 72 (60–85) were reviewed. Re-TUR was associated with improved recurrence and progression outcomes (HR~RFS~: 0.63; 95% CI 0.46–0.86; HR~PFS~: 0.55; 95% CI 0.31–0.86). Adjusting for CUETO risk factors and re-TUR, BGC TICE and RIVM provided longer RFS compared to Connaught (HR~TICE~: 0.58, 95% CI 0.39–0.86; HR~RIVM~: 0

Who reads Efficacy of three BCG strains (Connaught, TICE and RIVM) with or without secondary resection (re-TUR) for intermediate/high-risk non-muscle-invasive bladder cancers: results from a retrospective single-institution cohort analysis?

It is typically read by researchers, students, and practitioners in Medicine.

Author
Francesco Del Giudice; Gian Maria Busetto; Martin S. Gross; Martina Maggi; Alessandro Sciarra; Stefano Salciccia; Matteo Ferro; Isabella Sperduti; Simone Flammia; Vittorio Canale; Benjamin I. Chung; Simon L. Conti; Michael L. Eisenberg; Eila C. Skinner; Ettore De Berardinis
Publisher
Springer Science and Business Media LLC
Published
2021
Language
EN
Field
Medicine (Health Sciences)

More by Francesco Del Giudice; Gian Maria Busetto; Martin S. Gross; Martina Maggi; Alessandro Sciarra; Stefano Salciccia; Matteo Ferro; Isabella Sperduti; Simone Flammia; Vittorio Canale; Benjamin I. Chung; Simon L. Conti; Michael L. Eisenberg; Eila C. Skinner; Ettore De Berardinis

Browse all works by Francesco Del Giudice; Gian Maria Busetto; Martin S. Gross; Martina Maggi; Alessandro Sciarra; Stefano Salciccia; Matteo Ferro; Isabella Sperduti; Simone Flammia; Vittorio Canale; Benjamin I. Chung; Simon L. Conti; Michael L. Eisenberg; Eila C. Skinner; Ettore De Berardinis